Induction immunochemotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy for unresectable stage III non-small cell lung cancer: a multi-institutional retrospective cohort study.

Front Immunol · 2025 · PMC12350322 · PMID 40821769

Europe PMC DOI

hedged sentence

0.5300

closest p · 10.6× alpha

0.5300

boldest claim

The sentences

showed a trendp =0.530not close (p > 0.1)

Although the I-CRT-I group showed a trend toward reduced progression risk (HR = 0.91, 95% CI 0.68–1.22; p =0.530), no statistically significant improvement in PFS was observed compared with the CRT-I group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.